Presidio Pharmaceuticals Secures $27,000,000 Series B Financing

  • Feed Type
  • Date
    7/10/2009
  • Company Name
    Presidio Pharmaceuticals
  • Mailing Address
    1700 Owens Street San Francisco, CA 94158
  • Company Description
    Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
  • Website
    http://www.presidiopharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $27,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds raised will be used to advance Presidio’s HCV NS5A clinical candidate through clinical studies, and to support the development of other programs in the pipeline.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Panorama Capital
  • Venture Investor
    Baker Brothers Investments
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Nexus Medical Partners
  • Venture Investor
    Ventures West
  • Venture Investor
    Sagamore Bioventures

By posting a comment, you agree to our terms and conditions.